MedTrace Logo

Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies

NCT04470947 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2024-03-22

No results posted yet for this study

Summary

EXALT-2 is a prospective, randomized, three arm study for treatment decision guided either by either comprehensive genomic profiling, next generation drug screening or physician's choice

Conditions

  • Advanced Lymphoma
  • Refractory Lymphoma
  • Refractory Leukemia
  • Refractory Acute Myeloid Leukemia
  • Refractory T-Cell Lymphoma

Interventions

DIAGNOSTIC_TEST

Next generation functional drug screening

High-throughput image based in-vitro drug screening on primary patient tumor cells

DIAGNOSTIC_TEST

Comprehensive genomic profiling

Comprehensive targeted profiling of genetic aberrations on primary patient tumor material

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Allcyte GmbH

    collaborator UNKNOWN

  • Medical University of Vienna

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-10
Primary Completion
2026-03-31
Completion
2026-03-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04470947 on ClinicalTrials.gov